Introduction: The Growing Economic Challenge of Diabetes

Diabetes is one of the most costly chronic diseases worldwide. In the United States alone, the American Diabetes Association estimates that diagnosed diabetes accounts for approximately $412.9 billion in total direct and indirect costs each year, a figure that has climbed steadily as prevalence rises. The burden falls not only on patients and insurers but also on employers, government programs like Medicare and Medicaid, and the broader healthcare system. Much of this expense is driven by complications that result from suboptimal glycemic control: cardiovascular disease, kidney failure, neuropathy, amputations, and hospitalizations for acute metabolic events such as diabetic ketoacidosis and severe hypoglycemia.

For decades, the cornerstone of pharmacotherapy for people with type 1 diabetes and many with type 2 diabetes has been injectable insulin. While life-saving, injected insulin comes with well-documented barriers: needle phobia, social stigma, inconvenience of timing, and the burden of multiple daily injections. These challenges can undermine adherence and lead to poorer outcomes. Against this backdrop, Afrezza (insulin human) inhalation powder offers a fundamentally different delivery route that could shift the cost equation. This article explores how this rapid-acting inhaled insulin might reduce diabetes-related healthcare costs and considers the evidence, the obstacles, and the patients most likely to benefit.

Understanding Afrezza: Mechanism, Pharmacokinetics, and Clinical Profile

What Is Afrezza?

Afrezza is a dry-powder formulation of recombinant human insulin administered via oral inhalation using a small, breath-powered inhaler. It was approved by the U.S. Food and Drug Administration in 2014 as a prandial (mealtime) insulin for type 1 and type 2 diabetes in adults. The insulin is adsorbed onto a Technosphere particle, which dissolves rapidly upon contact with the moist surfaces of the deep lung, leading to fast absorption into the bloodstream.

How It Differs from Injectables

The pharmacokinetic profile of Afrezza distinguishes it from both human regular insulin and the analog rapid-acting injectables (lispro, aspart, glulisine). Its onset of action is as fast as 12–15 minutes, peaking in about 30–60 minutes, and the duration of action is roughly 90–180 minutes. This more closely mimics the endogenous insulin spike that occurs with eating, potentially allowing for tighter postprandial control. In contrast, injectable rapid-acting analogs typically peak at 60–90 minutes and can last 4–6 hours, a profile that sometimes leads to late postprandial hypoglycemia or stacking of doses.

Clinical Efficacy and Safety

Multiple randomized controlled trials, including the pivotal phase 3 studies (Affinity 1 and Affinity 2), demonstrated that Afrezza achieves comparable reductions in A1C to injectable rapid-acting insulin when used in combination with basal insulin for type 1 diabetes or as part of a regimen for type 2 diabetes. The rate of severe hypoglycemia in these trials was low, though mild cough was a common adverse event, occurring in roughly one-quarter of users. Pulmonary function tests (FEV1) showed small but statistically significant declines compared to injectable insulin, a finding that led to a boxed warning advising against use in patients with chronic lung diseases such as asthma or COPD. Long-term safety data from a five-year extension study suggest that the decline in lung function plateaus over time and does not progress.

The Heavy Price of Suboptimal Glycemic Control

Direct Medical Costs of Diabetes Complications

To understand how a new therapy might reduce costs, one must first appreciate where the money goes. According to the Centers for Disease Control and Prevention, hospital inpatient stays account for roughly 30% of diabetes-related healthcare spending, followed by prescription medications (including insulin), office visits, and emergency department care. The most expensive complications include cardiovascular disease (annual per-person costs exceeding $10,000 in those with diabetes), end-stage renal disease requiring dialysis or transplant, and lower-extremity amputations.

Acute Events: The Hidden Expense

Beyond chronic complications, acute metabolic emergencies contribute heavily to avoidable costs. The average cost of a single hospitalization for diabetic ketoacidosis (DKA) is approximately $17,000, and rates of DKA have been rising in the United States. In patients with type 2 diabetes, episodes of severe hypoglycemia requiring emergency services or hospitalization add billions in costs each year. Any intervention that reduces these events, even modestly, could produce substantial savings at a population level.

Adherence and Its Economic Impact

Non-adherence to prescribed insulin regimens is a major driver of poor outcomes and higher spending. Studies have shown that about 40–50% of patients with diabetes do not take their insulin as prescribed, often skipping doses due to fear of needles, inconvenience, or concerns about hypoglycemia. Inhaled insulin, being needle-free and discreet, has the potential to improve adherence, particularly for the mealtime doses that many patients find most burdensome.

Pathways to Cost Reduction: How Afrezza Could Save Money

Fewer Hospitalizations from Acute Events

Because Afrezza reaches its peak rapidly and clears quickly, the risk of late postprandial hypoglycemia may be lower than with injectable analogs. A post-hoc analysis of the Affinity trials found that the incidence of non-severe hypoglycemia (self-treated) was lower with Afrezza compared to injectable rapid-acting insulin. Even a small reduction in rates of severe hypoglycemic events could translate into decreased emergency department visits and inpatient stays. For patients with type 1 diabetes who struggle with erratic absorption from injection sites (e.g., due to lipohypertrophy), the predictable pulmonary absorption of Afrezza may reduce glucose variability and thereby lower the likelihood of both hyper- and hypoglycemic emergencies.

Improved Long-Term Glycemic Control

Optimal postprandial glucose control is critical for achieving overall A1C targets. Afrezza's PK/PD profile allows patients to time their dose at the start of a meal, rather than the traditional 15–30-minute pre-meal wait. This simplicity may encourage more consistent dosing. In the Affinity 2 trial for type 2 diabetes, patients receiving Afrezza plus basal insulin achieved non-inferior A1C reductions compared to those on premixed insulin or a regimen with injectable prandial insulin. Any improvement in glycemic control that is sustained over years will reduce the cumulative incidence of microvascular and macrovascular complications, the main drivers of long-term costs.

Reduced Need for Ancillary Medications

Afrezza is indicated only for prandial use. However, for some patients with type 2 diabetes, the ability to achieve tight postprandial control may allow clinicians to simplify regimens. For example, a patient on multiple daily injections plus a GLP-1 receptor agonist might be able to discontinue one component. While Afrezza itself is a branded product with a list price higher than many generic insulins, the net cost after discounts and rebates may be comparable, and any reduction in overall pill burden or injectable device waste yields savings.

Patient Satisfaction and Adherence

Patient-reported outcomes from surveys show that a majority of Afrezza users find the device easy to use and are satisfied with the dosing experience. Improved treatment satisfaction correlates with better adherence, and better adherence drives better outcomes. In a retrospective claims analysis published in Diabetes Technology & Therapeutics, patients using Afrezza had a lower rate of insulin discontinuation at 12 months compared to those on injectable prandial insulins. Lower discontinuation rates mean fewer patients experiencing uncontrolled hyperglycemia and its downstream complications.

Challenges and Considerations for Real-World Use

Pulmonary Safety: The Ongoing Concern

Afrezza carries a boxed warning about acute bronchospasm in patients with chronic lung disease and a caution about persistent declines in FEV1. Although the average decline observed in trials is small and non-progressive, spirometry monitoring is recommended before and after initiation. This adds an incremental cost (pulmonary function tests, office visits) that must be weighed against potential savings. For patients with underlying respiratory conditions, the risks generally outweigh the benefits, limiting the addressable patient population.

Insurance Coverage and Formulary Access

Despite being approved for nearly a decade, Afrezza has not achieved broad tier-1 (preferred) coverage across commercial and government plans. Many insurers place it on tier 3 or 4, requiring prior authorization or step therapy (e.g., failure on two injectable rapid-acting insulins). Patients who cannot obtain affordable access will not realize any cost savings. A 2022 analysis estimated that only about 40% of commercially insured patients had unrestricted access to Afrezza. Until formulary placement improves, the drug's cost-saving potential will remain constrained.

Patient and Provider Education Barriers

Prescribing inhaled insulin requires that clinicians become familiar with proper patient selection, inhaler technique, and dose conversion from injectable units. Many primary care providers and even endocrinologists have limited experience with the product. A recent survey found that only 15% of U.S. endocrinologists had prescribed Afrezza in the prior year. Without widespread adoption, the volume needed to generate population-level savings will not materialize. Moreover, patients must be taught to perform the inhalation maneuver correctly and to clean the inhaler.

Direct Drug Acquisition Costs

The list price of Afrezza is higher per unit than generic regular insulin or analog insulins. While net prices after rebates can be lower, the upfront cost to health plans and patients can be a deterrent. A cost-effectiveness analysis published in 2022 modeled the use of Afrezza versus injectable rapid-acting insulin in patients with type 1 diabetes and found that, under base-case assumptions, Afrezza was not cost-effective (incremental cost-effectiveness ratio >$200,000 per quality-adjusted life year). However, the model's conclusions were sensitive to assumptions about adherence improvement and hypoglycemia reduction. If real-world adherence is significantly higher with Afrezza, the cost-effectiveness ratio could improve dramatically.

Who Benefits Most? Targeting the Right Population

Patients with Needle Phobia or Injection Barriers

Individuals who actively avoid injections or who have developed lipohypertrophy from repeated injections may see the greatest adherence gain from switching to Afrezza. This population is at elevated risk for poor glycemic control and complications, so even modest improvements in adherence can yield outsized reductions in long-term costs.

Patients with High Postprandial Glucose Variability

Afrezza's rapid offset makes it an attractive option for patients who experience frequent late post-meal hypoglycemia or who have "dose stacking" issues. For example, a patient who eats a high-fat meal that delays gastric emptying might benefit from the shorter insulin duration if their usual analog causes a hypoglycemic dip 3–4 hours later. Better postprandial control translates into fewer glucose monitoring supplies, fewer correction doses, and fewer hypoglycemia-related calls to the care team.

Active Lifestyles and Travel

The compact, disposable inhaler and the lack of refrigeration requirements (once in use) make Afrezza convenient for travel and exercise. Patients who consistently skip mealtime doses when away from home may find it easier to take Afrezza, thus maintaining control and avoiding the skipped-dose hyperglycemia that ultimately costs the system.

Integrating Afrezza into a Cost-Conscious Care Model

Practical Steps for Healthcare Systems

For Afrezza to reduce population-level diabetes costs, health systems and payers must adopt several strategies:

  • Develop patient selection algorithms to identify patients most likely to benefit (needle averse, high postprandial variability, frequent hypoglycemia) and exclude those with pulmonary contraindications.
  • Simplify prior authorization processes by creating automated approvals for patients who meet criteria, reducing administrative waste.
  • Invest in education programs for providers and diabetes educators so that prescribing and follow-up are efficient.
  • Monitor real-world outcomes such as A1C change, hypoglycemia rates, and total cost of care for Afrezza initiators versus matched controls on injectables.

Potential for New Developments

MannKind Corporation, the manufacturer of Afrezza, continues to explore improvements. A next-generation formulation with a longer duration of action (Twist) is in development, which could potentially serve as a basal alternative. If a single-inhaler regimen replaces multiple injection devices, further cost and waste reductions are possible. Additionally, combination of Afrezza with a small GLP-1 receptor agonist in one inhaler is a theoretical future pathway.

Conclusion: A Tool, Not a Panacea

Afrezza is not likely to revolutionize diabetes care to the point of eliminating injectable insulin, but it offers a clinically meaningful alternative with a distinct set of trade-offs. Its potential to reduce healthcare costs rests on improving adherence, lowering acute event rates, and possibly delaying complications through better postprandial control. The available evidence, including the 2022 cost-effectiveness analysis, suggests that these benefits are plausible but not yet proven in large-scale real-world studies. Widespread adoption requires overcoming barriers of access, education, and formulary placement. For the subset of patients who are poorly served by injectable insulin, Afrezza may provide both clinical and economic value. As diabetes costs continue to rise, every tool that can safely bend the cost curve deserves careful consideration and ongoing evaluation.

For more information on the economics of diabetes, refer to the American Diabetes Association's 2023 Economic Costs Report. For clinical prescribing information, see the Afrezza official prescribing information.